Page last updated: 2024-08-05 12:17:08
imidazoquinoline
null
ChEBI ID: 38776
Members (6)
Member | Definition | Role |
---|---|---|
2-amino-3-methylimidazo(4,5-f)quinoline | An imidazoquinoline that is 3H-imidazo[4,5-f]quinoline substituted by a methyl group at position 3 and an amino group at position 2. | 3-methyl-3H-imidazo[4,5-f]quinolin-2-amine |
bgt226 | An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 3-trifluoromethyl-4-(piperazin-1-yl)phenyl group and at position 8 by a 6-methoxypyridin-3-yl group. A dual PI3K/mTOR inhibitor. | BGT226 free base |
dactolisib | An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment. | dactolisib |
gsk1210151a | 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one | |
imiquimod | An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. | imiquimod |
resiquimod | resiquimod |
Research
Studies (4,460)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 112 (2.51) | 18.7374 |
1990's | 280 (6.28) | 18.2507 |
2000's | 1,126 (25.25) | 29.6817 |
2010's | 2,073 (46.48) | 24.3611 |
2020's | 869 (19.48) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 314 (6.57%) | 5.53% |
Reviews | 496 (10.38%) | 6.00% |
Case Studies | 745 (15.59%) | 4.05% |
Observational | 16 (0.33%) | 0.25% |
Other | 3,209 (67.13%) | 84.16% |